KR20030014411A - 치환 퀴나졸린 유도체 및 저해제로서 그것의 용도 - Google Patents

치환 퀴나졸린 유도체 및 저해제로서 그것의 용도 Download PDF

Info

Publication number
KR20030014411A
KR20030014411A KR1020027017913A KR20027017913A KR20030014411A KR 20030014411 A KR20030014411 A KR 20030014411A KR 1020027017913 A KR1020027017913 A KR 1020027017913A KR 20027017913 A KR20027017913 A KR 20027017913A KR 20030014411 A KR20030014411 A KR 20030014411A
Authority
KR
South Korea
Prior art keywords
alkyl
compound
mmol
optionally substituted
formula
Prior art date
Application number
KR1020027017913A
Other languages
English (en)
Korean (ko)
Inventor
모틀록앤드류
중프레데릭
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20030014411A publication Critical patent/KR20030014411A/ko

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020027017913A 2000-06-28 2001-06-21 치환 퀴나졸린 유도체 및 저해제로서 그것의 용도 KR20030014411A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00401842 2000-06-28
EP00401842.0 2000-06-28

Publications (1)

Publication Number Publication Date
KR20030014411A true KR20030014411A (ko) 2003-02-17

Family

ID=8173742

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027017913A KR20030014411A (ko) 2000-06-28 2001-06-21 치환 퀴나졸린 유도체 및 저해제로서 그것의 용도

Country Status (27)

Country Link
US (2) US6919338B2 (is)
EP (1) EP1299381B1 (is)
JP (1) JP2004501914A (is)
KR (1) KR20030014411A (is)
CN (1) CN1267431C (is)
AR (1) AR030432A1 (is)
AT (1) ATE394102T1 (is)
AU (1) AU2001266505A1 (is)
BG (1) BG107376A (is)
BR (1) BR0111754A (is)
CA (1) CA2412592A1 (is)
CZ (1) CZ20024120A3 (is)
DE (1) DE60133897D1 (is)
EE (1) EE200200715A (is)
ES (1) ES2305081T3 (is)
HK (1) HK1053124A1 (is)
HU (1) HUP0301236A2 (is)
IL (1) IL153246A0 (is)
IS (1) IS6656A (is)
MX (1) MXPA02011974A (is)
NO (1) NO20026010D0 (is)
NZ (1) NZ522696A (is)
PL (1) PL360439A1 (is)
RU (1) RU2283311C2 (is)
SK (1) SK18102002A3 (is)
WO (1) WO2002000649A1 (is)
ZA (1) ZA200209412B (is)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110120321A (ko) * 2009-02-11 2011-11-03 메르크 파텐트 게엠베하 신규의 아미노 아자헤테로시클릭 카르복사미드

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
DE60120193T2 (de) * 2000-09-15 2007-03-29 Vertex Pharmaceuticals Inc., Cambridge Pyrazolverbindungen als protein-kinasehemmer
ATE528303T1 (de) * 2000-12-21 2011-10-15 Vertex Pharma Pyrazoleverbindungen als proteinkinasehemmer
CA2471577C (en) 2001-12-24 2011-08-02 Astrazeneca Ab Chemical compounds
SG159380A1 (en) * 2002-02-06 2010-03-30 Vertex Pharma Heteroaryl compounds useful as inhibitors of gsk-3
EP1482931B1 (en) * 2002-03-05 2011-10-19 TransTech Pharma, Inc. Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
DE60332604D1 (de) * 2002-03-15 2010-07-01 Vertex Pharma Azolylaminoazine als proteinkinasehemmer
JP4681302B2 (ja) 2002-05-06 2011-05-11 バーテックス ファーマシューティカルズ インコーポレイテッド チアジアゾールまたはオキサジアゾール、およびこれらの、jakプロテインキナーゼのインヒビターとしての使用
MY141867A (en) * 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
CA2491191C (en) 2002-07-15 2014-02-04 Exelixis, Inc. Receptor-type kinase modulators and methods of use
JP4733388B2 (ja) * 2002-08-02 2011-07-27 バーテックス ファーマシューティカルズ インコーポレイテッド Gsk−3のインヒビターとして有用なピラゾール組成物
GB0221245D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Chemical process
AU2003290322A1 (en) * 2002-12-24 2004-07-22 Astrazeneca Ab Quinazoline compounds
EP1578755B1 (en) 2002-12-24 2007-08-22 AstraZeneca AB Phosphonooxy quinazoline derivatives and their pharmaceutical use
CN101074227B (zh) * 2002-12-24 2010-09-29 阿斯利康(瑞典)有限公司 膦酰氧基喹唑啉衍生物及其药物用途
WO2004072029A2 (en) * 2003-02-06 2004-08-26 Vertex Pharmaceuticals Incorporated Pyrazolopyridazines useful as inhibitors of protein kinases
ATE390422T1 (de) * 2003-04-16 2008-04-15 Astrazeneca Ab Quinazolin-derivate für die behandling von krebs
EP1635823A1 (en) * 2003-05-20 2006-03-22 TransTech Pharma Inc. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
ES2308182T3 (es) * 2003-06-02 2008-12-01 Astrazeneca Ab Derivadosde (3-((quinazolin-4-il)amino)-1h-pirazol-1-il)acetamida y compuestos relacionados como inhibidores de quinasas aurora para el tratamiento de enfermedades proliferativas tales como el cancer.
TW200505452A (en) * 2003-06-17 2005-02-16 Astrazeneca Ab Chemical compounds
GB0320793D0 (en) * 2003-09-05 2003-10-08 Astrazeneca Ab Chemical process
ES2925655T3 (es) 2003-09-26 2022-10-19 Exelixis Inc Moduladores c-Met y métodos de uso
US20090143399A1 (en) * 2003-10-14 2009-06-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
JP4845736B2 (ja) * 2003-10-14 2011-12-28 アリゾナ ボード オブ リージェンツ オン ビハーフ ザ ユニバーシティー オブ アリゾナ プロテインキナーゼ阻害剤
US20090099165A1 (en) 2003-10-14 2009-04-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
US20080051414A1 (en) * 2003-10-14 2008-02-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
WO2005042498A2 (en) * 2003-10-31 2005-05-12 Neurogen Corporation 4-amino (aza) quinoline derivatives as capsaicin receptor agonists
AU2004297235A1 (en) * 2003-12-04 2005-06-23 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases
WO2005061519A1 (en) * 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
WO2005066152A1 (en) * 2003-12-30 2005-07-21 The Brigham And Women's Hospital, Inc. Thiophene derivatives for up-regulating hla-dm activity
CA2560286A1 (en) * 2004-03-23 2005-09-29 Banyu Pharmaceutical Co., Ltd. Substituted quinazoline or pyridopyrimidine derivative
JP2007533753A (ja) * 2004-04-23 2007-11-22 タケダ サン ディエゴ インコーポレイテッド インドール誘導体及びキナーゼ阻害剤としてのその使用
EP1778669A2 (en) * 2004-08-18 2007-05-02 Takeda San Diego, Inc. Kinase inhibitors
ATE540935T1 (de) 2004-10-12 2012-01-15 Astrazeneca Ab Chinazolinderivate
JP2008515960A (ja) * 2004-10-12 2008-05-15 アストラゼネカ アクチボラグ キノリン誘導体
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
CN1854130B (zh) * 2005-04-15 2011-04-20 中国医学科学院药物研究所 喹唑啉衍生物、及其制法和药物组合物与用途
GB0509227D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
GB0510963D0 (en) * 2005-05-28 2005-07-06 Astrazeneca Ab Chemical compounds
US7737151B2 (en) * 2005-08-18 2010-06-15 Vertex Pharmaceuticals Incorporated Pyrazine kinase inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
CA2627830A1 (en) * 2005-11-03 2007-05-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
EP1785420A1 (en) * 2005-11-14 2007-05-16 4Sc Ag Thiazole analogues and uses thereof
US7560551B2 (en) 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
KR101300424B1 (ko) 2006-01-23 2013-08-26 암젠 인크 오로라 키나제 조절제 및 사용 방법
US7868177B2 (en) * 2006-02-24 2011-01-11 Amgen Inc. Multi-cyclic compounds and method of use
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
EP1994024A2 (en) * 2006-03-02 2008-11-26 AstraZeneca AB Quinoline derivatives
WO2007113005A2 (en) * 2006-04-03 2007-10-11 European Molecular Biology Laboratory (Embl) 2-substituted 3-aminosulfonyl-thiophene derivatives as aurora kinase inhibitors
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
EP2073807A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
US8236823B2 (en) * 2006-10-27 2012-08-07 Amgen Inc. Multi-cyclic compounds and methods of use
US20080207632A1 (en) * 2006-10-31 2008-08-28 Supergen, Inc. Protein kinase inhibitors
JP2010509231A (ja) * 2006-11-02 2010-03-25 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼの阻害剤として有用なアミノピリジンおよびアミノピリミジン
AU2007333650A1 (en) * 2006-12-19 2008-06-26 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
AU2008226461A1 (en) 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyridines useful as inhibitors of protein kinases
EP2137183B1 (en) * 2007-03-09 2011-09-28 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
ES2435997T3 (es) * 2007-03-09 2013-12-26 Vertex Pharmaceuticals, Inc. Aminopirimidinas útiles como inhibidores de las proteínas cinasas
ES2470341T3 (es) * 2007-04-05 2014-06-23 Amgen, Inc Moduladores de la aurora cinasa y método de uso
JP2010523700A (ja) 2007-04-13 2010-07-15 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼインヒビターとして有用なアミノピリミジン
EP2155730A2 (en) * 2007-05-02 2010-02-24 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
CN101801959A (zh) * 2007-05-02 2010-08-11 沃泰克斯药物股份有限公司 可用作激酶抑制剂的氨基嘧啶类化合物
CA2685876A1 (en) * 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
GB0709031D0 (en) * 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
WO2008147626A2 (en) * 2007-05-24 2008-12-04 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
CA2690141A1 (en) * 2007-06-20 2008-12-24 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
EP2170842A1 (en) * 2007-06-21 2010-04-07 Irm, Llc Protein kinase inhibitors and methods for using thereof
CN101790532B (zh) * 2007-07-31 2013-11-20 沃泰克斯药物股份有限公司 5-氟-1H-吡唑并[3,4-b]吡啶-3-胺及其衍生物的制备方法
DE102008015032A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte Pyrazolamide und ihre Verwendung
DE102008015033A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
MX2010010151A (es) * 2008-03-20 2010-10-25 Amgen Inc Moduladores de cinasa aurora y metodo de uso.
US9126935B2 (en) 2008-08-14 2015-09-08 Amgen Inc. Aurora kinase modulators and methods of use
MX2011002312A (es) * 2008-09-03 2011-04-26 Vertex Pharma Co-cristales y formulaciones farmaceuticas que comprenden los mismos.
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
CA2995883C (en) 2008-12-03 2023-01-24 The Scripps Research Institute Compounds and methods for stabilizing cell cultures
DE102008062878A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte Furancarboxamide und ihre Verwendung
DE102008062863A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte (Thiophenyl-carbonyl)imidazolidinone und ihre Verwendung
TWI447108B (zh) 2009-01-16 2014-08-01 Exelixis Inc N-(4-{〔6,7雙(甲氧基)喹啉-4-基〕氧基}苯基)-n’-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽及其結晶型
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EP2470510B1 (en) 2009-09-30 2014-05-14 TransTech Pharma, LLC Substituted imidazole derivatives for treatment of alzheimers disease.
EP2558461B1 (en) 2010-04-14 2015-12-02 Bristol-Myers Squibb Company Novel glucokinase activators and methods of using same
JP5898687B2 (ja) * 2010-11-18 2016-04-06 カシナ ライラ イノバ ファーマシューティカルズ プライベート リミテッド 置換4−(セレノフェン−2(または3)−イルアミノ)ピリミジン化合物およびその使用方法
US9090633B2 (en) 2010-11-18 2015-07-28 Kasina Laila Innova Pharmaceuticals Private Limited Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof
US8785459B2 (en) * 2011-12-27 2014-07-22 Development Center For Biotechnology Quinazoline compounds as kinase inhibitors
GB201202027D0 (en) 2012-02-06 2012-03-21 Sareum Ltd Pharmaceutical compounds
EP2634185B1 (en) 2012-03-02 2016-01-13 Sareum Limited TYK2 kinase inhibitors
CN103788085B (zh) * 2012-10-31 2016-09-07 复旦大学 2-(喹唑啉-4-氨基)-5-噻唑甲酰胺类衍生物及其生物药物用途
CN104098551B (zh) * 2013-04-03 2019-03-22 广东东阳光药业有限公司 作为欧若拉激酶抑制剂的取代喹唑啉类衍生物
RU2682332C2 (ru) 2013-09-16 2019-03-19 Астразенека Аб Терапевтические полимерные наночастицы и способы их получения и применения
BR112018006873A2 (pt) 2015-10-05 2018-11-06 The Trustees Of Columbia University In The City Of New York ativadores do fluxo autofágico e fosfolipase d e depuração de agregados de proteína incluindo tau e tratamento de proteinopatias
GB201617871D0 (en) 2016-10-21 2016-12-07 Sareum Limited Pharmaceutical compounds
AR112027A1 (es) * 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol
JP2022547882A (ja) * 2019-09-06 2022-11-16 インフレイゾーム リミテッド Nlrp3阻害剤
CN110746398A (zh) * 2019-10-18 2020-02-04 刘沛友 4-杂环取代喹唑啉类衍生物及其制备方法和用途
CN111574473A (zh) * 2020-06-04 2020-08-25 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) 一种氨基噻唑类化合物的合成方法
CN113311166B (zh) * 2021-04-28 2022-10-28 新疆农垦科学院 一种用于绵羊早期妊娠诊断的蛋白生物标志物及其用于绵羊早期妊娠检测的方法
CN115557601A (zh) * 2022-11-08 2023-01-03 成都理工大学 生物质微球及其制备方法与应用、生物反应器、地下井

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870725A (en) * 1971-03-30 1975-03-11 Lilly Industries Ltd Nitrothiazole derivatives
WO1992020642A1 (en) 1991-05-10 1992-11-26 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
NZ243082A (en) * 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
IL117620A0 (en) * 1995-03-27 1996-07-23 Fujisawa Pharmaceutical Co Heterocyclic compounds processes for the preparation thereof and pharmaceutical compositions containing the same
GB9514265D0 (en) * 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
US6716575B2 (en) * 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
CN1161352C (zh) * 1998-10-08 2004-08-11 阿斯特拉曾尼卡有限公司 喹唑啉衍生物
GB9922171D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110120321A (ko) * 2009-02-11 2011-11-03 메르크 파텐트 게엠베하 신규의 아미노 아자헤테로시클릭 카르복사미드

Also Published As

Publication number Publication date
CA2412592A1 (en) 2002-01-03
NO20026010L (no) 2002-12-13
CZ20024120A3 (cs) 2003-03-12
NZ522696A (en) 2004-08-27
NO20026010D0 (no) 2002-12-13
AU2001266505A1 (en) 2002-01-08
WO2002000649A1 (en) 2002-01-03
HUP0301236A2 (hu) 2003-10-28
RU2283311C2 (ru) 2006-09-10
US20030187002A1 (en) 2003-10-02
AR030432A1 (es) 2003-08-20
WO2002000649A9 (en) 2007-09-20
US6919338B2 (en) 2005-07-19
IS6656A (is) 2002-12-17
PL360439A1 (en) 2004-09-06
ZA200209412B (en) 2004-02-19
CN1496364A (zh) 2004-05-12
ATE394102T1 (de) 2008-05-15
CN1267431C (zh) 2006-08-02
HK1053124A1 (en) 2003-10-10
SK18102002A3 (sk) 2003-07-01
US20060046987A1 (en) 2006-03-02
EP1299381A1 (en) 2003-04-09
JP2004501914A (ja) 2004-01-22
BR0111754A (pt) 2003-04-29
EP1299381B1 (en) 2008-05-07
DE60133897D1 (de) 2008-06-19
EE200200715A (et) 2004-08-16
ES2305081T3 (es) 2008-11-01
BG107376A (bg) 2003-09-30
IL153246A0 (en) 2003-07-06
MXPA02011974A (es) 2004-09-06

Similar Documents

Publication Publication Date Title
KR20030014411A (ko) 치환 퀴나졸린 유도체 및 저해제로서 그것의 용도
US7081461B1 (en) Quinazoline compounds and pharmaceutical compositions containing them
US7105669B1 (en) Quinazoline derivatives
US7402585B2 (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
US6977259B2 (en) Quinoline derivatives and their use as aurora 2 kinase inhibitors
CZ20021008A3 (cs) Deriváty chinazolinu, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje
SK3822002A3 (en) Quinazoline derivatives, process for the preparation thereof and their use
CZ300293B6 (cs) Nové amidové deriváty, zpusob jejich prípravy a farmaceutická kompozice, která je obsahuje
MXPA02008371A (es) Compuestos de pirimidina.
JP2009504694A (ja) 1−アシルジヒドロピラゾール誘導体
KR101674695B1 (ko) 피리다지논 유도체
KR101669696B1 (ko) 피리다지논 유도체

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application